Community-based studies revealed a higher prevalence of LV systolic and diastolic dysfunction using the new echocardiographic imaging techniques. Future prospective studies will clarify the ...

Diastolic heart failure is defined clinically when signs and symptoms of heart failure are present in the presence of preserved left ventricular systolic function (ejection fraction >45%).

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

In a population with a history of heart failure plus renal insufficiency, diabetes, or left ventricular systolic dysfunction, the SGLT2 inhibitor reduced risk of the composite of death from any ...

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), ...

Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

All patients had a prior hospitalization for HF and at least one of the following: diabetes (44%), left ventricular systolic dysfunction (17%) or poor kidney function (89%). This was an older ...

and echocardiography variables for predicting left ventricular systolic dysfunction in patients with isolated left ventricular dilation Session Date & Time: Saturday, March 29, 9:30 AM CDT ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.